MYLAN-NAPROXEN/ESOMEPRAZOLE MR 375 MG
NAPROXEN : 375 MG ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) : 20 MG · DIN 02458608 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MYLAN-NAPROXEN/ESOMEPRAZOLE MR?
MYLAN-NAPROXEN/ESOMEPRAZOLE MR 375 MG contains NAPROXEN : 375 MG ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02458608, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET (IMMEDIATE AND DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Feb-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02458608 |
|---|---|
| Brand name | MYLAN-NAPROXEN/ESOMEPRAZOLE MR |
| Generic / active ingredient | NAPROXEN : 375 MG ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM) : 20 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 375 MG |
| Dosage form | TABLET (IMMEDIATE AND DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AE52 NAPROXEN AND ESOMEPRAZOLE |
| AHFS class | 28:08.04.92 ; 56:28.36 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Feb-2017 |
| Original market date | 2017-02-27 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M01AE52 NAPROXEN AND ESOMEPRAZOLE. 4 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-NAPROXEN/ESOMEPRAZOLE MR | 500 MG | TABLET (IMMEDIATE AND DELAYED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02443449 |
| VIMOVO | 20 MG | TABLET (IMMEDIATE AND DELAYED-RELEASE) | XEDITON PHARMACEUTICALS INC | MARKETED | DIN 02361701 |
| VIMOVO | 20 MG | TABLET (IMMEDIATE AND DELAYED-RELEASE) | XEDITON PHARMACEUTICALS INC | MARKETED | DIN 02361728 |
Who else supplies NAPROXEN AND ESOMEPRAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NAPROXEN AND ESOMEPRAZOLE appears in 1493 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.